FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2140521678> ?p ?o ?g. }

• W2140521678 abstract "Abstract Background Patients with advanced melanoma are faced with a poor prognosis and, until recently, limited treatment options. Ipilimumab, a novel immunotherapy that blocks cytotoxic T-lymphocyte-associated antigen-4, was the first agent to improve survival of patients with advanced melanoma in a randomised, controlled phase 3 trial. We used data from an expanded access programme (EAP) at Italian centres to evaluate the clinical activity and safety profile of ipilimumab 10 mg/kg in patients with advanced melanoma in a setting more similar to that of daily practice. Methods Data were collected from patients enrolled in an ipilimumab EAP across eight participating Italian centres. As per the EAP protocol, patients had life-threatening, unresectable stage III/IV melanoma, had failed or did not tolerate previous treatments and had no other therapeutic option available. Treatment comprised ipilimumab 10 mg/kg every 3 weeks for a total of four doses. If physicians believed patients would continue to derive benefit from ipilimumab treatment, maintenance therapy with ipilimumab 10 mg/kg was provided every 12 weeks. Tumour responses were assessed every 12 weeks using modified World Health Organization criteria and safety continuously monitored. Results Seventy-four pretreated patients with advanced melanoma were treated with ipilimumab 10 mg/kg. Of these, 9 (13.0%) had an objective response, comprising 3 patients with a complete response and 6 with a partial response. Median overall survival was 7.0 months (95% confidence interval, 5.3–8.7) and 16.6% of patients were alive after 3 years. Forty-five patients (60.8%) reported treatment-related adverse events of any grade, which were most commonly low-grade pruritus, pain, fever and diarrhoea. Grade 3 or 4 treatment-related AEs were reported in 8 patients (10.8%). Conclusions The clinical activity and safety profile of ipilimumab 10 mg/kg in the EAP was similar to that seen in previous clinical trials of ipilimumab in pretreated patient populations." @default.
• W2140521678 created "2016-06-24" @default.
• W2140521678 creator A5001201465 @default.
• W2140521678 creator A5004497401 @default.
• W2140521678 creator A5008516429 @default.
• W2140521678 creator A5008685924 @default.
• W2140521678 creator A5018536695 @default.
• W2140521678 creator A5021447572 @default.
• W2140521678 creator A5029398339 @default.
• W2140521678 creator A5030289522 @default.
• W2140521678 creator A5031591368 @default.
• W2140521678 creator A5044347261 @default.
• W2140521678 creator A5056290263 @default.
• W2140521678 creator A5057849200 @default.
• W2140521678 creator A5070704228 @default.
• W2140521678 creator A5071929183 @default.
• W2140521678 creator A5074959680 @default.
• W2140521678 creator A5086743021 @default.
• W2140521678 date "2013-10-25" @default.
• W2140521678 modified "2023-10-11" @default.
• W2140521678 title "Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme" @default.
• W2140521678 cites W2008497077 @default.
• W2140521678 cites W2016055985 @default.
• W2140521678 cites W2017622305 @default.
• W2140521678 cites W2038388329 @default.
• W2140521678 cites W2042293669 @default.
• W2140521678 cites W2054535181 @default.
• W2140521678 cites W2095826876 @default.
• W2140521678 cites W2097995306 @default.
• W2140521678 cites W2100158834 @default.
• W2140521678 cites W2102031533 @default.
• W2140521678 cites W2102143045 @default.
• W2140521678 cites W2109653150 @default.
• W2140521678 cites W2112069616 @default.
• W2140521678 cites W2118863192 @default.
• W2140521678 cites W2119198740 @default.
• W2140521678 cites W2123363005 @default.
• W2140521678 cites W2129623370 @default.
• W2140521678 cites W2133441070 @default.
• W2140521678 cites W2137723371 @default.
• W2140521678 cites W2138134458 @default.
• W2140521678 cites W2148586726 @default.
• W2140521678 cites W2158299227 @default.
• W2140521678 cites W2159516794 @default.
• W2140521678 cites W2164918836 @default.
• W2140521678 cites W2494190851 @default.
• W2140521678 doi "https://doi.org/10.1186/1756-9966-32-82" @default.
• W2140521678 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4029467" @default.
• W2140521678 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24423086" @default.
• W2140521678 hasPublicationYear "2013" @default.
• W2140521678 type Work @default.
• W2140521678 sameAs 2140521678 @default.
• W2140521678 citedByCount "23" @default.
• W2140521678 countsByYear W21405216782014 @default.
• W2140521678 countsByYear W21405216782015 @default.
• W2140521678 countsByYear W21405216782016 @default.
• W2140521678 countsByYear W21405216782017 @default.
• W2140521678 countsByYear W21405216782018 @default.
• W2140521678 countsByYear W21405216782019 @default.
• W2140521678 countsByYear W21405216782020 @default.
• W2140521678 countsByYear W21405216782021 @default.
• W2140521678 crossrefType "journal-article" @default.
• W2140521678 hasAuthorship W2140521678A5001201465 @default.
• W2140521678 hasAuthorship W2140521678A5004497401 @default.
• W2140521678 hasAuthorship W2140521678A5008516429 @default.
• W2140521678 hasAuthorship W2140521678A5008685924 @default.
• W2140521678 hasAuthorship W2140521678A5018536695 @default.
• W2140521678 hasAuthorship W2140521678A5021447572 @default.
• W2140521678 hasAuthorship W2140521678A5029398339 @default.
• W2140521678 hasAuthorship W2140521678A5030289522 @default.
• W2140521678 hasAuthorship W2140521678A5031591368 @default.
• W2140521678 hasAuthorship W2140521678A5044347261 @default.
• W2140521678 hasAuthorship W2140521678A5056290263 @default.
• W2140521678 hasAuthorship W2140521678A5057849200 @default.
• W2140521678 hasAuthorship W2140521678A5070704228 @default.
• W2140521678 hasAuthorship W2140521678A5071929183 @default.
• W2140521678 hasAuthorship W2140521678A5074959680 @default.
• W2140521678 hasAuthorship W2140521678A5086743021 @default.
• W2140521678 hasBestOaLocation W21405216781 @default.
• W2140521678 hasConcept C121608353 @default.
• W2140521678 hasConcept C126322002 @default.
• W2140521678 hasConcept C141071460 @default.
• W2140521678 hasConcept C143998085 @default.
• W2140521678 hasConcept C2775832928 @default.
• W2140521678 hasConcept C2777658100 @default.
• W2140521678 hasConcept C2777701055 @default.
• W2140521678 hasConcept C2781433595 @default.
• W2140521678 hasConcept C44249647 @default.
• W2140521678 hasConcept C502942594 @default.
• W2140521678 hasConcept C535046627 @default.
• W2140521678 hasConcept C71924100 @default.
• W2140521678 hasConceptScore W2140521678C121608353 @default.
• W2140521678 hasConceptScore W2140521678C126322002 @default.
• W2140521678 hasConceptScore W2140521678C141071460 @default.
• W2140521678 hasConceptScore W2140521678C143998085 @default.
• W2140521678 hasConceptScore W2140521678C2775832928 @default.
• W2140521678 hasConceptScore W2140521678C2777658100 @default.
• W2140521678 hasConceptScore W2140521678C2777701055 @default.
• W2140521678 hasConceptScore W2140521678C2781433595 @default.
• W2140521678 hasConceptScore W2140521678C44249647 @default.

• next